Table 3.
Proportion of remission
| Time point | All groups | Aripiprazole group | Blonanserin group | Paliperidone group | χ2 test (p value) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total (N) | Remission rate | Total (n) | Remission rate | Total (n) | Remission rate | Total (n) | Remission rate | |||||||
| n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | |||||||
| Before the start of the study treatment | 251 | 74 (29.5) | 23.9–35.5 | 82 | 23 (28.0) | 18.7–39.1 | 85 | 23 (27.1) | 18.0–37.8 | 84 | 28 (33.3) | 23.4–44.5 | 0.6312 | |
| Initiation of single agent | 224 | 61 (27.2) | 21.5–33.6 | 75 | 23 (30.7) | 20.5–42.4 | 76 | 18 (23.7) | 14.7–34.8 | 73 | 20 (27.4) | 17.6–39.1 | 0.6281 | |
| Week 8 | 186 | 37 (19.9) | 14.4–26.4 | 62 | 14 (22.6) | 12.9–35.0 | 62 | 10 (16.1) | 8.0–27.7 | 62 | 13 (21.0) | 11.7–33.2 | 0.6449 | |
| Week 12 | 157 | 37 (23.6) | 17.2–31.0 | 53 | 13 (24.5) | 13.8–38.3 | 50 | 11 (22.0) | 11.5–36.0 | 54 | 13 (24.1) | 13.5–37.6 | 0.9498 | |
| Week 26 | 112 | 31 (27.7) | 19.6–36.9 | 38 | 11 (28.9) | 15.4–45.9 | 37 | 7 (18.9) | 8.0–35.2 | 37 | 13 (35.1) | 20.2–52.5 | 0.2899 | |
| Week 52 | All patients evaluated | 82 | 34 (41.5) | 30.7–52.9 | 26 | 11 (42.3) | 23.4–63.1 | 27 | 11 (40.7) | 22.4–61.2 | 29 | 12 (41.4) | 23.5–61.1 | 0.9933 |
| aOnly for 104-week patients | 53 | 23 (43.4) | 29.8–57.7 | 14 | 6 (42.9) | 17.7–71.1 | 15 | 6 (40.0) | 16.3–67.7 | 24 | 11 (45.8) | 25.6–67.2 | 0.9370 | |
| Week 104 | 53 | 24 (45.3) | 31.6–59.6 | 14 | 6 (42.9) | 17.7–71.1 | 15 | 7 (46.7) | 21.3–73.4 | 24 | 11 (45.8) | 25.6–67.2 | 0.9764 | |
CI confidence interval
aRemission rates were calculated for patients who completed 104 weeks of continuation to compare the proportion at 104 weeks